NASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $482.00 +1.50 (+0.31%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$480.22 -1.78 (-0.37%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$473.56▼$484.9950-Day Range$425.09▼$529.5952-Week Range$362.50▼$533.67Volume1.11 million shsAverage Volume1.86 million shsMarket Capitalization$122.33 billionP/E Ratio28.59Dividend YieldN/APrice Target$559.61Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals Inc. is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets. Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms. Its approved therapies include potentiators and corrector combinations that have expanded treatment options for people with different CFTR mutations. These drugs, introduced progressively since the early 2010s, are the cornerstone of Vertex’s commercial business and have enabled broad access programs and partnerships to reach CF patients globally. Beyond cystic fibrosis, Vertex has invested heavily in next‑generation technologies and new therapeutic areas. The company is advancing programs in gene editing and cell therapy, including a collaboration with CRISPR Therapeutics to develop gene‑editing treatments for hemoglobinopathies such as sickle cell disease and beta‑thalassemia, and it has pursued stem cell–derived approaches for type 1 diabetes following its acquisition of Semma Therapeutics. Vertex’s pipeline also includes earlier‑stage research across other serious diseases where precision genetic or cell‑based approaches may offer durable benefit. Vertex maintains a commercial presence in North America, Europe and other international markets while sustaining a large R&D footprint to support discovery and clinical development. The company is led by Chief Executive Officer Reshma Kewalramani and a management team with deep experience in both clinical development and commercial operations. Vertex emphasizes patient access, long‑term innovation and collaboration with academic and industry partners as it seeks to expand its impact beyond cystic fibrosis into additional rare and serious diseases. AI Generated. May Contain Errors. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreVRTX MarketRank™: Vertex Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 169th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 22 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialVertex Pharmaceuticals has a consensus price target of $559.61, representing about 16.1% upside from its current price of $482.00.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth10.70% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 10.70% in the coming year, from $17.01 to $18.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 28.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 28.59, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.97.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 2.09. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vertex Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.95% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently increased by 6.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.14 News SentimentVertex Pharmaceuticals has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Vertex Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 29 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat Follows35 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,707,966.00 in company stock.Percentage Held by Insiders0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRTX Stock News HeadlinesBiotech IPO Gains Crush AI Listings With Standout 55% ReturnJuly 21 at 12:46 PM | finance.yahoo.comA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpJuly 21 at 12:46 PM | finance.yahoo.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead. | Stansberry Research (Ad)Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market TodayJuly 20 at 7:56 PM | finance.yahoo.comVertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2July 20 at 9:28 AM | finance.yahoo.comVertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.July 8, 2026 | marketbeat.comOurania Tatsis Sells 1,500 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) StockJuly 8, 2026 | insidertrades.comCarmen Bozic Sells 1,020 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) StockJune 24, 2026 | insidertrades.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $453.36 at the beginning of 2026. Since then, VRTX stock has increased by 6.3% and is now trading at $482.00. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Monday, May, 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.24 by $0.23. The firm's revenue was up 8.3% compared to the same quarter last year. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and more. Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.30%), Handelsbanken Fonder AB (0.09%), Czech National Bank (0.03%) and Atwood & Palmer Inc. (0.02%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose and Sangeeta N Bhatia. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), Qualcomm (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings5/04/2026Today7/21/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 VRTX's financial health is in the Green zone, according to TradeSmith. VRTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,400Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$559.61 High Price Target$641.00 Low Price Target$436.00 Potential Upside/Downside+16.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$16.86 Trailing P/E Ratio28.59 Forward P/E Ratio28.34 P/E Growth2.09Net Income$3.95 billion Net Margins35.51% Pretax Margin42.28% Return on Equity23.86% Return on Assets17.13% Debt Debt-to-Equity RatioN/A Current Ratio3.02 Quick Ratio2.57 Sales & Book Value Annual Sales$12.00 billion Price / Sales10.19 Cash Flow$17.63 per share Price / Cash Flow27.34 Book Value$73.57 per share Price / Book6.55Miscellaneous Outstanding Shares253,800,000Free Float253,297,000Market Cap$122.33 billion OptionableOptionable Beta0.29 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VRTX) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
